Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspirin + rosuvastatin
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aspirin + rosuvastatin is a fixed-dose combination of two pharmaceutical agents used primarily for the prevention of cardiovascular events such as heart attack and stroke. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) with antiplatelet properties, acting by irreversibly inhibiting cyclooxygenase 1 (COX1), thereby reducing thromboxane A2 production and preventing platelet aggregation. Rosuvastatin is an HMG-CoA reductase inhibitor (statin) that lowers cholesterol by inhibiting the enzyme responsible for cholesterol synthesis in the liver, leading to reduced low-density lipoprotein (LDL) cholesterol and increased high-density lipoprotein (HDL) cholesterol. The combination targets both lipid lowering and antithrombotic pathways to reduce the risk of atherosclerotic cardiovascular disease[1][2][5][6].
- Brand names
- DanavishRozucor ASPRozavel ARoseday-AJupiros-AConsivas-AspRazel-AArvast-ARosumac ASPRosukem-ARozustat-AS
- Other names
- rosuvastatin + aspirin
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on aspirin + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aspirin + rosuvastatin.